$TVTX
Travere Therapeutics Inc

2023 Q3 Form 10-Q Financial Statement

#000143853323000039 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $37.10M $59.70M
YoY Change -30.66% 10.21%
Cost Of Revenue $1.289M $1.990M
YoY Change -23.04% -2.97%
Gross Profit $35.81M $57.71M
YoY Change -30.9% 10.73%
Gross Profit Margin 96.53% 96.67%
Selling, General & Admin $67.80M $63.11M
YoY Change 17.88% 19.13%
% of Gross Profit 189.36% 109.37%
Research & Development $60.59M $66.99M
YoY Change 2.25% 12.25%
% of Gross Profit 169.22% 116.09%
Depreciation & Amortization $5.590M $13.90M
YoY Change -34.83% 71.48%
% of Gross Profit 15.61% 24.09%
Operating Expenses $128.4M $145.3M
YoY Change 9.95% 28.96%
Operating Profit -$92.59M -$87.58M
YoY Change 35.89% 33.81%
Interest Expense $2.800M $2.217M
YoY Change -196.82% -174.6%
% of Operating Profit
Other Income/Expense, Net $3.356M -$201.0K
YoY Change -343.72% -86.85%
Pretax Income -$89.23M -$85.57M
YoY Change 28.37% 27.75%
Income Tax $12.00K $65.00K
% Of Pretax Income
Net Earnings $150.7M -$85.63M
YoY Change -316.4% 27.74%
Net Earnings / Revenue 406.35% -143.44%
Basic Earnings Per Share $1.97 -$1.13
Diluted Earnings Per Share $1.97 -$1.13
COMMON SHARES
Basic Shares Outstanding 75.01M shares 74.61M shares
Diluted Shares Outstanding 76.31M shares 76.00M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $356.9M $491.3M
YoY Change -20.36% -3.43%
Cash & Equivalents $144.2M $70.87M
Short-Term Investments $212.6M $420.5M
Other Short-Term Assets $16.20M $11.56M
YoY Change 89.5% 24.49%
Inventory $20.77M $18.77M
Prepaid Expenses
Receivables $14.60M $20.40M
Other Receivables $0.00 $0.00
Total Short-Term Assets $686.2M $542.1M
YoY Change 28.31% -7.62%
LONG-TERM ASSETS
Property, Plant & Equipment $7.996M $28.13M
YoY Change -16.33% 179.06%
Goodwill $800.0K $900.0K
YoY Change -11.11% 0.0%
Intangibles $106.9M $154.5M
YoY Change -28.48% 3.03%
Long-Term Investments
YoY Change
Other Assets $12.92M $11.79M
YoY Change 16.41% 9.09%
Total Long-Term Assets $146.6M $194.4M
YoY Change -23.39% 0.86%
TOTAL ASSETS
Total Short-Term Assets $686.2M $542.1M
Total Long-Term Assets $146.6M $194.4M
Total Assets $832.9M $736.4M
YoY Change 14.68% -5.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $24.74M $19.92M
YoY Change 76.56% 68.09%
Accrued Expenses $95.71M $65.16M
YoY Change 8.29% -21.21%
Deferred Revenue $8.959M $10.24M
YoY Change -21.29% -18.07%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $139.4M $135.7M
YoY Change 6.41% 9.01%
LONG-TERM LIABILITIES
Long-Term Debt $376.8M $376.4M
YoY Change 0.45% 0.46%
Other Long-Term Liabilities $8.381M $107.8M
YoY Change -9.92% 1022.64%
Total Long-Term Liabilities $8.381M $484.2M
YoY Change -9.92% 4941.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $139.4M $135.7M
Total Long-Term Liabilities $8.381M $484.2M
Total Liabilities $553.1M $619.9M
YoY Change -11.58% -0.46%
SHAREHOLDERS EQUITY
Retained Earnings -$1.035B -$1.186B
YoY Change 9.18% 34.99%
Common Stock $7.000K $7.000K
YoY Change 16.67% 16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $279.8M $116.5M
YoY Change
Total Liabilities & Shareholders Equity $832.9M $736.4M
YoY Change 14.68% -5.52%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $150.7M -$85.63M
YoY Change -316.4% 27.74%
Depreciation, Depletion And Amortization $5.590M $13.90M
YoY Change -34.83% 71.48%
Cash From Operating Activities -$59.14M -$69.30M
YoY Change 49.63% 88.28%
INVESTING ACTIVITIES
Capital Expenditures $4.930M $3.836M
YoY Change -164.59% -133.47%
Acquisitions
YoY Change
Other Investing Activities $138.3M -$19.72M
YoY Change 680.54% -28.65%
Cash From Investing Activities $133.3M -$23.55M
YoY Change 1222.75% -39.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -630.0K 2.266M
YoY Change -127.66% 172.68%
NET CHANGE
Cash From Operating Activities -59.14M -69.30M
Cash From Investing Activities 133.3M -23.55M
Cash From Financing Activities -630.0K 2.266M
Net Change In Cash 73.55M -90.58M
YoY Change -370.72% 20.66%
FREE CASH FLOW
Cash From Operating Activities -$59.14M -$69.30M
Capital Expenditures $4.930M $3.836M
Free Cash Flow -$64.07M -$73.13M
YoY Change 100.9% 188.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006CumulativeEffectPeriodOfAdoptionMember
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8570000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9049000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19559000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21000000 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
154456000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
145038000 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11789000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11061000 usd
CY2023Q2 us-gaap Assets
Assets
736429000 usd
CY2022Q4 us-gaap Assets
Assets
672585000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
19915000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17290000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
88749000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
95742000 usd
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10244000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11976000 usd
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
6900000 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
7000000 usd
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
67200000 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
64200000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25106000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27510000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8736000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9385000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
619944000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
629734000 usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74971807 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74971807 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64290570 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64290570 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
7000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1306517000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1059975000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1186184000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1014223000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3855000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2907000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
116485000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
42851000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
736429000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
672585000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
116690000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
102654000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7115000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4189000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
129324000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
116292000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
146282000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
99767000 usd
CY2023Q2 tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
1840000 usd
CY2022Q2 tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
4907000 usd
tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
8596000 usd
tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
13987000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-85630000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-67032000 usd
us-gaap Net Income Loss
NetIncomeLoss
-171961000 usd
us-gaap Net Income Loss
NetIncomeLoss
-143003000 usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.13
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.13
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.26
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76001801 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76001801 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63638385 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63638385 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72109573 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72109573 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63387009 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63387009 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-85630000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-67032000 usd
us-gaap Net Income Loss
NetIncomeLoss
-171961000 usd
us-gaap Net Income Loss
NetIncomeLoss
-143003000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-170000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1416000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-736000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1487000 usd
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1509000 usd
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-803000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-212000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2007000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-87309000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66419000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-172909000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-143523000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
189140000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
208141000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11172000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
12352000 usd
CY2023Q2 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
793000 usd
CY2022Q2 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
824000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2689000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1815000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-170000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1416000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1509000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-803000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-85630000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-67032000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
116485000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
156713000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
42851000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
302112000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
24497000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
20287000 usd
us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
3089000 usd
us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
947000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3128000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2065000 usd
tvtx Pre Funded Common Stock Warrants Net Of Issuance Costs
PreFundedCommonStockWarrantsNetOfIssuanceCosts
1600000 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
24630000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-736000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1487000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-212000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2007000 usd
us-gaap Net Income Loss
NetIncomeLoss
-171961000 usd
us-gaap Net Income Loss
NetIncomeLoss
-143003000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
116485000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
156713000 usd
us-gaap Net Income Loss
NetIncomeLoss
-143003000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
25368000 usd
tvtx Net Changein Fair Valueof Contingent Consideration
NetChangeinFairValueofContingentConsideration
8596000 usd
tvtx Net Changein Fair Valueof Contingent Consideration
NetChangeinFairValueofContingentConsideration
13987000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-4890000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-4247000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3329000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-895000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-7578000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1367000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3980000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3735000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
777000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
13022000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2060000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-933000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2336000 usd
tvtx Change In Lease Assets And Liabilities Net
ChangeInLeaseAssetsAndLiabilitiesNet
-492000 usd
tvtx Change In Lease Assets And Liabilities Net
ChangeInLeaseAssetsAndLiabilitiesNet
-492000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2512000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2917000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-7904000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
9070000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6823000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-5700000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-483000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2127000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-150414000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-92126000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
196871000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
217325000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
225660000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
206529000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
31170000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
16579000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
633000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
148000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60592000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5931000 usd
tvtx Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
1050000 usd
tvtx Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
1050000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
863000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1271000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
316250000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
9882000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
211324000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
24630000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3089000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
947000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2258000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1529000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
219262000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
114744000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
930000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2681000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9186000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14006000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61688000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165753000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70874000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179759000 usd
us-gaap Nature Of Operations
NatureOfOperations
DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Travere Therapeutics, Inc. (“we”, “our”, “us”, “Travere” and the “Company”) refers to Travere Therapeutics, Inc., a Delaware corporation, as well as its subsidiaries. Travere is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. The Company regularly evaluates and, where appropriate, acts on opportunities to expand its product pipeline through licenses and acquisitions of products in areas that will serve patients with serious </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">unmet medical need</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and that the Company believes offer attractive growth characteristics.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#006ebf;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FILSPARI™ (sparsentan)</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 17, 2023, the U.S. Food and Drug Administration (the "FDA") granted accelerated approval of FILSPARI™ (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally at UPCR ≥1.5 gram/gram. FILSPARI, a once-daily, oral medication is designed to selectively target two critical pathways (endothelin 1 and angiotensin-II) in the disease progression of IgAN. </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical-Stage Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The continued approval of FILSPARI for IgAN may be contingent upon confirmation of a clinical benefit in the Company's ongoing Phase 3 clinical trial of sparsentan for the treatment of IgAN (the "PROTECT Study"), which is designed to demonstrate whether FILSPARI slows kidney function decline. Topline results from the two-year confirmatory endpoints in the PROTECT Study are expected in the fourth quarter of 2023 and are intended to support traditional approval of FILSPARI.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sparsentan remains a novel investigational product candidate which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis (FSGS) in the U.S. and Europe. The double-blind portion of the Phase 3 study of sparsentan for FSGS has recently concluded and, following release of the top-line data from the study which showed that the study did not meet its primary endpoint, the Company is conducting further analyses of the data and is preparing to engage with regulators to explore a potential path forward toward a potential regulatory submission in FSGS.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pegtibatinase (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TVT-058) is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU). Pegtibatinase has been granted Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations by the FDA, as well as orphan drug designation in the United States and European Union. Pegtibatinase is currently being evaluated in the Phase 1/2 COMPOSE Study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects in patients with classical HCU. In May 2023, the Company announced positive topline results from cohort 6 in the Phase 1/2 COMPOSE Study. The Company</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> acquired pegtibatinase as part of the November 2020 acquisition of Orphan Technologies Limited.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chenodal (chenodeoxycholic acid or CDCA) is a naturally occurring bile acid that is approved for the treatment of people with radiolucent stones in the gallbladder. In September 2022, the Company was granted Fast Track Designation by the FDA for the investigation of Chenodal for cerebrotendinous xanthomatosis (CTX). In January 2020, the Company randomized the first patients in its Phase 3 RESTORE Study to evaluate the effects of Chenodal in adult and pediatric patients with CTX, and the study enrollment remains open. The pivotal study is intended to support an NDA submission for marketing authorization of Chenodal for CTX in the United States. In July 2023, the Company entered into an Asset Purchase Agreement to sell substantially all of the Company’s assets that are primarily related to the Company’s business of development, manufacture (including synthesis, formulation, finishing or packaging) and commercialization of Chenodal and Cholbam. See Note 18.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is a participant in a Cooperative Research and Development Agreement ("CRADA"), which forms a multi-stakeholder approach to pool resources with leading experts, and incorporate the patient perspective early in the therapeutic identification and development process. The Company is partnering with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and a leading patient advocacy organization, Alagille Syndrome Alliance, aimed at the identification of potential small molecule therapeutics for Alagille syndrome ("ALGS"). There are no treatment options currently approved for ALGS.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is party to a collaboration agreement with PharmaKrysto Limited and their early-stage cystinuria discovery program, whereby the Company is responsible for funding all research and development expenses for the pre-clinical activities associated with the cystinuria program.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commercial Products:</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Thiola</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Thiola EC</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Cholbam</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div>•Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
420463000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1990000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2051000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7115000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4189000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7500000 usd
CY2023Q2 tvtx Cost Of Goods And Services Sold Potential Increase
CostOfGoodsAndServicesSoldPotentialIncrease
100000 usd
tvtx Cost Of Goods And Services Sold Potential Increase
CostOfGoodsAndServicesSoldPotentialIncrease
100000 usd
tvtx Number Of Phase One Half Clinical Trials
NumberOfPhaseOneHalfClinicalTrials
1 clinicaltrial
CY2023Q2 tvtx Number Of Phase3 Clinical Trials In Process
NumberOfPhase3ClinicalTrialsInProcess
3 clinicaltrial
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
388557000 usd
CY2023Q2 tvtx Debt Securities Availableforsale Amortized Cost Basis Current
DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent
232338000 usd
CY2023Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3700000 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3700000 usd
us-gaap Revenue Performance Obligation Description Of Timing
RevenuePerformanceObligationDescriptionOfTiming
For FILSPARI, sales are recognized upon delivery of the product to the specialty pharmacies. The Company receives payments from its FILSPARI sales based on terms that are generally 30 days from shipment of the product to the specialty pharmacy. For the Company's other products, product sales are recognized upon delivery to the patient. The Company receives payments from sales of its other products, primarily through third party payers, based on terms that generally are within 30 days of delivery of product to the patient.
CY2023Q2 tvtx Debt Securities Available For Sale Unrealized Gain Current
DebtSecuritiesAvailableForSaleUnrealizedGainCurrent
8000 usd
CY2023Q2 tvtx Debt Securities Available For Sale Unrealized Loss Current
DebtSecuritiesAvailableForSaleUnrealizedLossCurrent
1237000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
231109000 usd
CY2023Q2 tvtx Debt Securities Availableforsale Amortized Cost Basis Noncurrent
DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent
191291000 usd
CY2023Q2 tvtx Debt Securities Available For Sale Unrealized Gain Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent
33000 usd
CY2023Q2 tvtx Debt Securities Available For Sale Unrealized Loss Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent
1970000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
189354000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
423629000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
41000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3207000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
420463000 usd
CY2022Q4 tvtx Debt Securities Availableforsale Amortized Cost Basis Current
DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent
287615000 usd
CY2022Q4 tvtx Debt Securities Available For Sale Unrealized Gain Current
DebtSecuritiesAvailableForSaleUnrealizedGainCurrent
2000 usd
CY2022Q4 tvtx Debt Securities Available For Sale Unrealized Loss Current
DebtSecuritiesAvailableForSaleUnrealizedLossCurrent
2091000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
285526000 usd
CY2022Q4 tvtx Debt Securities Availableforsale Amortized Cost Basis Noncurrent
DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent
103897000 usd
CY2022Q4 tvtx Debt Securities Available For Sale Unrealized Gain Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent
39000 usd
CY2022Q4 tvtx Debt Securities Available For Sale Unrealized Loss Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent
905000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
103031000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
391512000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
41000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2996000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
388557000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
196900000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
225700000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
217300000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
206500000 usd
CY2023Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
2500000 usd
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1900000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
351833000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2777000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
44620000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
430000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
396453000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3207000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
248321000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1960000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
112420000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1036000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
360741000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2996000 usd
CY2023Q2 tvtx Debt Securities Available For Sale Unrealized Loss Position Amortized Cost
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost
399700000 usd
CY2022Q4 tvtx Debt Securities Available For Sale Unrealized Loss Position Amortized Cost
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost
363700000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
70874000 usd
CY2023Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3174000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6501000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6673000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6889000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7064000 usd
CY2023Q2 tvtx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
4781000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
35082000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5313000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
29769000 usd
CY2023Q2 tvtx Operating Lease Incentive Tenant Improvements
OperatingLeaseIncentiveTenantImprovements
5083000 usd
CY2023Q2 tvtx Straight Line Lease Expense In Excess Of Cash Payments
StraightLineLeaseExpenseInExcessOfCashPayments
5127000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19559000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y8M12D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0648
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0648
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
2500000 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
2500000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
420463000 usd
CY2023Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
491337000 usd
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
74100000 usd
CY2023Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
74100000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
61688000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
388557000 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
450245000 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
71200000 usd
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
71200000 usd
us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
2 business
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
71200000 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
67100000 usd
tvtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue
8596000 usd
tvtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue
13987000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
2756000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
2685000 usd
tvtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Accrued
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsAccrued
2940000 usd
tvtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Accrued
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsAccrued
2702000 usd
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
74100000 usd
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
75700000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
334685000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
302935000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
181165000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
158833000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
153520000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
144102000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
900000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
900000 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
35267000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
13345000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7571000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
22332000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
14127000 usd
CY2022Q1 tvtx Debt Instrument Repurchase Amount Including Accrued And Unpaid Interest
DebtInstrumentRepurchaseAmountIncludingAccruedAndUnpaidInterest
213800000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-7600000 usd
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
3400000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
2900000 usd
us-gaap Interest Expense
InterestExpense
5900000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
3000000 usd
us-gaap Interest Expense
InterestExpense
5500000 usd
CY2023Q2 tvtx Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
28254000 usd
CY2022Q4 tvtx Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
26070000 usd
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
21489000 usd
CY2023Q2 tvtx Government Rebates Payable
GovernmentRebatesPayable
14376000 usd
CY2022Q4 tvtx Government Rebates Payable
GovernmentRebatesPayable
13486000 usd
CY2023Q2 tvtx Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
11252000 usd
CY2022Q4 tvtx Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
8791000 usd
CY2023Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
8467000 usd
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
7755000 usd
CY2023Q2 tvtx Accrued Liabilities Miscellaneous
AccruedLiabilitiesMiscellaneous
4911000 usd
CY2022Q4 tvtx Accrued Liabilities Miscellaneous
AccruedLiabilitiesMiscellaneous
4373000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
88749000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
95742000 usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.13
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.13
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-67032000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-67032000 usd
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72109573 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72109573 shares
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-171961000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-171961000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.38
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63387009 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63387009 shares
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-143003000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-143003000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.26
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26044635 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24171946 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25785521 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22147717 shares
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
22100000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7500000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
20.71
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11603000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12637000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25367000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20823000 usd
CY2023Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
14652000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3627000 usd
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4113000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3295000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
18765000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
6922000 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20400000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16600000 usd
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001438533-23-000039-index-headers.html Edgar Link pending
0001438533-23-000039-index.html Edgar Link pending
0001438533-23-000039.txt Edgar Link pending
0001438533-23-000039-xbrl.zip Edgar Link pending
ex06302023102.htm Edgar Link pending
ex06302023311.htm Edgar Link pending
ex06302023312.htm Edgar Link pending
ex06302023321.htm Edgar Link pending
ex06302023322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tvtx-20230630.htm Edgar Link pending
tvtx-20230630.xsd Edgar Link pending
tvtx-20230630_g1.jpg Edgar Link pending
tvtx-20230630_def.xml Edgar Link unprocessable
tvtx-20230630_lab.xml Edgar Link unprocessable
tvtx-20230630_pre.xml Edgar Link unprocessable
tvtx-20230630_htm.xml Edgar Link completed
tvtx-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable